Catalyst Pharmaceuticals, Inc.
CPRX
$21.02
$0.150.72%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 163.89M | 142.80M | 68.15M | 65.12M | 71.41M |
| Total Depreciation and Amortization | 37.77M | 37.46M | 36.58M | 35.71M | 32.88M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 7.23M | 10.20M | 88.07M | 82.93M | 76.63M |
| Change in Net Operating Assets | 30.91M | 34.12M | 4.04M | -20.31M | -37.32M |
| Cash from Operations | 239.81M | 224.58M | 196.84M | 163.46M | 143.60M |
| Capital Expenditure | -556.00K | -36.56M | -36.37M | -36.36M | -198.52M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -2.23M | -94.98M | -94.98M | -94.98M |
| Cash from Investing | -556.00K | -38.79M | -131.34M | -131.33M | -293.50M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 154.52M | 149.22M | 145.46M | 144.04M | 2.79M |
| Repurchase of Common Stock | -668.00K | -657.00K | -657.00K | -709.00K | -982.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -13.18M | -13.00M | -13.39M | -13.29M | -12.67M |
| Cash from Financing | 140.67M | 135.57M | 131.41M | 130.04M | -10.86M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 379.92M | 321.36M | 196.91M | 162.16M | -160.76M |
